Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | ASCT: time to move on?

Ola Landgren • 13 Sep 2019
IMW 2019
Multiple Myeloma Melphalan

Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, explains why he thinks autologous stem-cell transplantation will not remain the standard of care in myeloma in five years. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Ola Landgren

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Ola Landgren • 7 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Ola Landgren • 8 Dec 2025
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
Trends in the evolving myeloma treatment landscape: observations from ASCO 2025
3:42
Trends in the evolving myeloma treatment landscape: observations from ASCO 2025
Ola Landgren • 6 Jun 2025

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Ola Landgren • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Ola Landgren • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Ola Landgren • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Ola Landgren • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals